Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CTRB1 | P17538 | 3/20 | 0.46 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682930 | 0.87 | LMNA (0.64) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL28033840 | 0.78 | LMNA (0.63) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL9815318 | 0.76 | LMNA (0.61) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4679419 | 0.76 | HPGD (0.69) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL11568901 | 0.75 | LMNA (0.59) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL10589495 | 0.75 | LMNA (0.59) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL4679156 | 0.74 | LMNA (0.62) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL28641833 | 0.73 | HDAC3 (0.58) | LMNAHPGDALDH1A1SMN1; SMN2CTRB1 | |
| SCHEMBL28274372 | 0.73 | LMNA (0.58) | LMNAHPGDALDH1A1MEN1KMT2A | |
| SCHEMBL27243970 | 0.73 | LMNA (0.68) | LMNAHPGDALDH1A1SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023133502-A1 | TREATMENT AND PREVENTION OF TRIGEMINAL NEURALGIA | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-07-13 | — | — | WO | disclosed |
| EP-3917510-A1 | TRANSIENT RECEPTOR POTENTIAL MELASTATIN 8 (TRPM8) ANTAGONISTS AND RELATED METHODS | Marshall University Research Corporation (US) | 2021-12-08 | — | — | EP | disclosed |
| WO-2020160464-A1 | TRANSIENT RECEPTOR POTENTIAL MELASTATIN 8 (TRPM8) ANTAGONISTS AND RELATED METHODS | MARSHALL UNIVERSITY RESEARCH CORPORATION (US) | 2020-08-06 | — | — | WO | disclosed |
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | ELI LILLY AND COMPANY | 2017-06-01 | — | — | US | disclosed |
| US-9260430-B2 | Use of TRPA1 antagonists to prevent or treat infections caused by biological-warfare agents | HYDRA BIOSCIENCES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130310345-A1 | Use of TRPA1 Antagonists to Prevent or Treat Infections Caused by Biological-Warfare Agents | ELI LILLY AND COMPANY | 2013-11-21 | — | — | US | disclosed |
| WO-2012050641-A2 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | HYDRA BIOSCIENCES, INC (US) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310345-A1 | Use of TRPA1 Antagonists to Prevent or Treat Infections Caused by Biological-Warfare Agents | TRPA1, TRPV1, TRPV2 | LMNA 2770/4885HPGD 1562/4885ALDH1A1 934/4885 |
| US-20170151248-A1 | USE OF TRPA1 ANTAGONISTS TO PREVENT OR TREAT INFECTIONS CAUSED BY BIOLOGICAL-WARFARE AGENTS | TRPA1, TRPV1, TRPV2 | LMNA 2770/4885HPGD 1562/4885ALDH1A1 934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.